open access

Vol 6, No 1 (2017)
Original articles (submitted)
Published online: 2017-06-20
Get Citation

Antidiabetic medications use and cancer risk in type 2 diabetes

Mariusz Dąbrowski, Elektra Szymańska-Garbacz, Zofia Miszczyszyn, Tadeusz Dereziński, Leszek Czupryniak
DOI: 10.5603/DK.2017.0004
·
Clinical Diabetology 2017;6(1):17-25.

open access

Vol 6, No 1 (2017)
Original articles (submitted)
Published online: 2017-06-20

Abstract

Introduction. The risk of several types of cancer is increased in type 2 diabetes mellitus (T2DM). Impact of antidiabetic medications on this risk is still a matter of controversies. The aim of our observational study was to evaluate the risk of cancer occurrence associated with the most frequently used antidiabetic agents.

Material and methods. 213 patients (118 women) with T2DM who developed cancer while treated for diabetes and 213 subjects with T2DM without cancer, matched by age and gender in a 1:1 case-control manner were included. Date of cancer diagnosis was considered as index time, and for each comparator data from the same calendar time were used.

Results. Both in the univariate and in multiple logistic regression analysis metformin use was associated with reduced cancer risk, while elevated risk associated with insulin use was significant only in univariate but not in multiple logistic regression analysis. Insulin and sulfonylurea derivatives in monotherapy were associated with significantly higher cancer risk compared to metformin monotherapy, while in combination with metformin this risk was attenuated to non-significant level.

Conclusion. Our study suggests protective effect of metformin and potentially negative impact of insulin and sulfonylurea derivatives on cancer risk. These findings should be interpreted with caution, due to relatively small study group. Nevertheless, to minimize cancer risk associated with antidiabetic medications’ use, metformin should be continued as long as medically acceptable and it should be combined with insulin or SU to neutralize risk associated with using either of the latter drugs in monotherapy.

Abstract

Introduction. The risk of several types of cancer is increased in type 2 diabetes mellitus (T2DM). Impact of antidiabetic medications on this risk is still a matter of controversies. The aim of our observational study was to evaluate the risk of cancer occurrence associated with the most frequently used antidiabetic agents.

Material and methods. 213 patients (118 women) with T2DM who developed cancer while treated for diabetes and 213 subjects with T2DM without cancer, matched by age and gender in a 1:1 case-control manner were included. Date of cancer diagnosis was considered as index time, and for each comparator data from the same calendar time were used.

Results. Both in the univariate and in multiple logistic regression analysis metformin use was associated with reduced cancer risk, while elevated risk associated with insulin use was significant only in univariate but not in multiple logistic regression analysis. Insulin and sulfonylurea derivatives in monotherapy were associated with significantly higher cancer risk compared to metformin monotherapy, while in combination with metformin this risk was attenuated to non-significant level.

Conclusion. Our study suggests protective effect of metformin and potentially negative impact of insulin and sulfonylurea derivatives on cancer risk. These findings should be interpreted with caution, due to relatively small study group. Nevertheless, to minimize cancer risk associated with antidiabetic medications’ use, metformin should be continued as long as medically acceptable and it should be combined with insulin or SU to neutralize risk associated with using either of the latter drugs in monotherapy.

Get Citation

Keywords

type 2 diabetes, cancer, metformin, sulfonylurea derivatives, insulin

About this article
Title

Antidiabetic medications use and cancer risk in type 2 diabetes

Journal

Clinical Diabetology

Issue

Vol 6, No 1 (2017)

Pages

17-25

Published online

2017-06-20

DOI

10.5603/DK.2017.0004

Bibliographic record

Clinical Diabetology 2017;6(1):17-25.

Keywords

type 2 diabetes
cancer
metformin
sulfonylurea derivatives
insulin

Authors

Mariusz Dąbrowski
Elektra Szymańska-Garbacz
Zofia Miszczyszyn
Tadeusz Dereziński
Leszek Czupryniak

References (34)
  1. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33(7): 1674–1685.
  2. Gallagher EJ, LeRoith D. Diabetes, antihyperglycemic medications and cancer risk: smoke or fire? Curr Opin Endocrinol Diabetes Obes. 2013; 20(5): 485–494.
  3. Dąbrowski M. Cukrzyca i nowotwory [Diabetes and cancer]. In: Czupryniak L. ed. Diabetologia. Kompendium [Diabetology. Compendium]. Wydawnictwo Medyczne Termedia, Poznań 2014: 408–421.
  4. Coperchini F, Leporati P, Rotondi M, et al. Expanding the therapeutic spectrum of metformin: from diabetes to cancer. J Endocrinol Invest. 2015; 38(10): 1047–1055.
  5. Karlstad O, Starup-Linde J, Vestergaard P, et al. Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr Drug Saf. 2013; 8(5): 333–348.
  6. Suissa S, Azoulay L. Metformin and the Risk of Cancer: Time-related biases in observational studies. Diabetes Care. 2012; 35(12): 2665–2673.
  7. Dąbrowski M, Szymańska-Garbacz E, Miszczyszyn Z, et al. Risk factors for cancer development in type 2 diabetes: A retrospective case-control study. BMC Cancer. 2016; 16(1): 785.
  8. Czeleko T, Śliwczyński A, Karnafel W. Cukrzyca zwiększa zapadalność i umieralność z powodu niektórych nowotworów złośliwych w Polsce: Analiza bazy danych Narodowego Funduszu Zdrowia obejmującej 1 840 973 osoby z cukrzycą w okresie 2008-2014 [Diabetes mellitus increases the incidence and mortality due the certain types of cancer in Poland: Analysis of the National Health Fund data base comprising 1 840 973 diabetes mellitus cases in the period 2008-2014]. Med Metab. 2015; XIX (1): 28-35. (in Polish).
  9. Evans JMM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330(7503): 1304–1305.
  10. Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52(9): 1766–1777.
  11. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32(9): 1620–1625.
  12. Kowall B, Stang A, Rathmann W, et al. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. Pharmacoepidemiol Drug Saf. 2015; 24(8): 865–874.
  13. Suissa S, Azoulay L. Metformin and cancer: mounting evidence against an association. Diabetes Care. 2014; 37(7): 1786–1788.
  14. Franciosi M, Lucisano G, Lapice E, et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013; 8(8): e71583.
  15. Hardie DG. AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes. 2013; 62(7): 2164–2172.
  16. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995; 333(9): 550–554.
  17. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012; 2(9): 778–790.
  18. Eikawa S, Nishida M, Mizukami S, et al. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A. 2015; 112(6): 1809–1814.
  19. Monami M, Lamanna C, Balzi D, et al. Sulphonylureas and cancer: a case-control study. Acta Diabetol. 2009; 46(4): 279–284.
  20. Chen Y, Du L, Li L, et al. Cancer risk of sulfonylureas in patients with type 2 diabetes mellitus: A systematic review. J Diabetes. 2017; 9(5): 482–494.
  21. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371(9612): 569–578.
  22. Garg SK, Maurer H, Reed K, et al. Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab. 2014; 16(2): 97–110.
  23. Janghorbani M, Dehghani M, Salehi-Marzijarani M. Systematic review and meta-analysis of insulin therapy and risk of cancer. Horm Cancer. 2012; 3(4): 137–146.
  24. Li C, Zhao G, Okoro CA, et al. Prevalence of diagnosed cancer according to duration of diagnosed diabetes and current insulin use among U.S. adults with diagnosed diabetes: findings from the 2009 Behavioral Risk Factor Surveillance System. Diabetes Care. 2013; 36(6): 1569–1576.
  25. Holden SE, Jenkins-Jones S, Morgan CLl, et al. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. Diabetes Obes Metab. 2015; 17(4): 350–362.
  26. Forssas E, Sund R, Manderbacka K, et al. Increased cancer mortality in diabetic people treated with insulin: a register-based follow-up study. BMC Health Serv Res. 2013; 13: 267.
  27. Monami M, Colombi C, Balzi D, et al. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care. 2011; 34(1): 129–131.
  28. de Beer JC, Liebenberg L. Does cancer risk increase with HbA1c, independent of diabetes? Br J Cancer. 2014; 110(9): 2361–2368.
  29. Wojciechowska U, Didkowska J. Morbidity and mortality of cancer in Poland. The National Cancer Registry, Cancer Centre - Institute for them. Maria Sklodowska - Curie. Available at http://onkologia.org. pl/k/epidemiologia/ Accessed 9th October. ; 2016.
  30. Dąbrowski M, Grondecka A. Diabetes as a risk factor of hospitalization in the surgical ward due to cancer in the elderly and middle-aged population. Archives of Medical Science. 2016.
  31. Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer. 2011; 18: R125–R147.
  32. Gerstein H. Does Insulin Therapy Promote, Reduce, or Have a Neutral Effect on Cancers? JAMA. 2010; 303(5): 446.
  33. Gerstein HC, Bosch J, Dagenais GR, et al. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012; 367(4): 319–328.
  34. Wu JW, Filion KB, Azoulay L, et al. Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies. Diabetes Care. 2016; 39(3): 486–494.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl